Evaluation of the Effectiveness of a Product Containing Topical Hydrocortisone in the Treatment of Seborrheic Dermatitis of the Face (13244/2009)
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Clinical single-blind randomized comparison with the overall objective of evaluating the clinical efficacy of the products Nutracort lotion and Nutracort cream in the treatment of seborrheic dermatitis on the face.
Will be held clinical and perceived efficacy assessment and instrumental measurements. Each product will be applied at half face for 7 consecutive days and all applications will be monitored in the research site. 60 volunteers will be recruited.
Evaluations will be held at the following times: T0 - before the initial application of the product; T1 - 24 hours after starting treatment, T2 - 48 hours after starting treatment, T3 - 72 hours after initiation of treatment, T4 - 96 hours after the start treatment, T7 - 7 days after initiation of treatment.
| Condition |
|---|
|
Seborrheic Dermatitis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Avaliação da eficácia de um Produto de Uso tópico Contendo Hidrocortisona no Tratamento de Dermatite seborréica na Face. |
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Healthy subjects with seborrheic dermatitis on both sides of the face, both sexes, aged 18 to 60 years, skin types I through IV.
Inclusion Criteria:
- Healthy subjects
- Subjects with seborrheic dermatitis on both sides of the face
- both sexes
- aged 18 to 60 years
- skin types I through IV.
Exclusion Criteria:
- pregnancy / lactation
- skin condition in the area of application of the product
- diabetes
- immune insufficiency
- subjects that are using systemic corticoids
- subjects that are using immunosuppressors
- skin diseases: vitiligo, psoriasis, lupus, atopic dermatitis
- history of reaction to the product category
- other diseases or medications that might interfere directly in the study or endanger the health of the subject
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Douglas - P&D, Galderma |
| ClinicalTrials.gov Identifier: | NCT01024374 History of Changes |
| Other Study ID Numbers: | All-E-M-13244-01/02-10-09 |
| Study First Received: | November 30, 2009 |
| Last Updated: | December 1, 2009 |
| Health Authority: | Brazil: National Health Surveillance Agency |
Additional relevant MeSH terms:
|
Dermatitis Dermatitis, Seborrheic Skin Diseases |
Sebaceous Gland Diseases Skin Diseases, Eczematous Skin Diseases, Papulosquamous |
ClinicalTrials.gov processed this record on May 16, 2013